Xenon Pharmaceuticals triggered a sharp sell-off after reporting adverse events in trials evaluating azetukalner, a treatment candidate for depression and bipolar disorder. The decision to voluntarily pause enrollment sent shares down to $42.35 in after-hours trading, reflecting investor anxiety over the drug's safety profile.
In section Market Quotes
Clinical Setbacks and Regulatory Wins Shift Pharma Valuations
A 26% plunge for Xenon Pharmaceuticals highlights the volatility of clinical development, as the company halts enrollment for its depression drug azetukalner. While investors retreated from the biotech firm, the market rewarded Ultragenyx Pharmaceutical for a rare disease milestone and signaled confidence in the capital allocation strategy of BRT Apartments.
Conversely, Ultragenyx Pharmaceutical secured a significant victory as the Food and Drug Administration approved its therapy, Fayuvi, for children suffering from Sanfilippo syndrome type A. The positive regulatory news drove the stock up 13% to $14.50 during regular hours, with an additional 1.7% gain following the announcement. Separately, BRT Apartments bolstered its market position by authorizing a $10 million expansion of its stock-buyback program, pushing shares to $14.22 in late trading.
Comments (0)
No comments yet. Be the first!